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INTRODUCTION
Among all the administration routes the oral one is the most favorable, however the low oral bioavailability of numerous drugs is a major issue and strategies able to improve drug solubility and adsorption are needed. One of the main causes of low drug oral bioavailability is the presence of a barrier that covers all the surface of the GI tract, namely the mucus barrier.
This continuous gel layer is a complex matrix formed mainly by mucin, a polypeptide with highly glycosylated negatively charged regions, hydrophobic regions and cysteine rich regions interconnected via disulfide bonds. Mucus is a semipermeable barrier that guaranties the exchange of nutrients, gases and water and prevents the permeation of many pathogens and foreign particles [1] . In recent years many attempts have been undertaken to formulate drug delivery systems (DDSs) able to overcome this barrier. A strategy that showed potential was a nanoparticulate system bearing mucolytic agents able to cleave the mucus substructure in front of them and therefore to cross this barrier. An in vivo study showed a prolonged residence time, compared to not functionalized NPs, in the small intestine of rats [2] . As this preliminary study showed great potential, it is worth to continue working in this direction to further improve such systems and the analytical methods needed behind. Accordingly, it was the aim of this study to compare the features of the papain (PAP) conjugated nanoparticles (NPs) with a new carrier bearing bromelain (BRO). The chosen enzymes are stable in simulated intestinal fluid as demonstrated by in vitro studies and their maintained mucolytic activity and ability to permeate through the intestine was demonstrated by several in vivo studies [3] [4] [5] [6] . However the enzymes are digested in gastric environment and therefore enteric coat is necessary for in vivo application. Both enzymes are known to decrease the intestinal mucus viscosity [7] but, to our knowledge, a systematic comparison between PAP and BRO modified NPs has not been performed yet. BRO was selected for the formulation of functionalized NPs in order to improve the tolerability of the carrier. In fact, beside the known occupational allergy caused by both enzymes (means a long term work 4 related exposure) [8] [9] [10] [11] , just one case of allergic reaction associated with BRO ingestion could be found in the literature [12] , while several cases of non-occupational allergic sensi tizati on were reported f or PAP [13, 14] . Moreover, a seri es of clinical tri als were performed in the past decade, last one published in 2013, illustrating the good tolerability to BRO ingestion by patients [15] [16] [17] [18] . Poly(acrylic) acid was chosen as polymeric backbone for this DDS as it shows weak mucoadhesive properties [19] and bears carboxylic groups to which enzymes can be conjugated via carbodiimide chemistry [20] . The reaction can take place at the amino terminal group of both enzymes and at lysine residues, which are 10 for PAP and 15 for BRO [21, 22] . To further investigate and gain a deeper understanding of the enhancing permeation properties of this new DDS, the results obtained with previously established techniques were correlated with the results obtained exploiting innovative techniques (such as pulsed-gradient spin-echo NMR, small-angle neutron scattering and spinecho small angle neutron scattering) yielding information on the effect of these NPs on the structure of mucus at small lengthcales. 5 [24] ) was dissolved in 500 mL of water and slowly added to the reaction mixture and stirred for 24 h at 10°C. The obtained enzyme-polymer conjugate was dialyzed against demineralized water for 3 days at 10°C. The solutions were then lyophilized yielding a white powder referred as PAA-PAP and PAA-BRO, respectively [2] .
MATERIALS AND METHODS
3.3. Nanoparticles formulation 100 mg of PAA or enzyme-polymer conjugate were dissolved in 10 mL water to obtain a 1wt% solution and the pH was adjusted to 8. This mixture was slowly added to 7.5 mL of Lumogen aceton solution 0.07 mg/mL. After 10 min equilibration 1 mL of CaCl 2 5 mg/mL dissolved in water was added drop by drop and stirred for 30 min. The suspension was then centrifuged at 5500 rpm (4966 x g) for 25 min (MiniSpin centrifuge, Eppendorf), the supernatant discarded and the pellet washed with 50vol% aceton/water mixture for three times.
Finally the washed pellet was resuspended in 1wt% trehalose/water solution by means of probe sonication for 10 sec and then lyophilized. The obtained products were referred to PAA NPs when PAA was used for the formulation, PAA-PAP NPs when PAA-PAP was used for the formulation and PAA-BRO NPs when PAA-BRO was used for the formulation.
Nanoparticles characterization
Nanoparticle particle size and charge characterization was carried out by using a NICOMPTM 380 ZLS PSS (Particle Sizing Systems, CA, USA). Particle size was recorded at a scattering angle of 90° for 10 min at room temperature. Zeta potential was recorded under electric field strength of 5 V/cm for 3 minutes at room temperature.
Enzyme quantification
The amount of enzyme conjugated to polymers and nanoparticles was determined by micro BCA protein assay, following the provider´s instruction. The samples were dissolved in 0.1 M NaOH solution containing 1.5wt% of sodium dodecyl sulfate to obtain a concentration of 0.1 mg/mL. The samples were incubated at 25°C in a thermomixer (Thermomixer Conform;
Eppendorf, Hamburg, Germany) under constant shaking, 1000 rpm for 2 h. Thereafter, 150 µL of sample were mixed with 150 µL of working reagent in a 96 well plate and incubated for further 2 h at 37°C. Finally the absorbance was detected at 562 nm by using a microplate reader (TECAN Infinite M200, Austria GmbH). The amount of enzyme was extrapolated by fitting the data to a calibration curve obtained via analyzing solution with different concentration of PAP or BRO. The enzyme content of polymers and NPs was reported on a weighted base as the ratio between the amount of conjugated enzyme and the amount of polymers or NPs. The conjugation efficacy onto the polymers was calculated as weight percent of the amount of conjugated enzyme relative to the initial amount of enzyme used.
Enzymatic activity assay
The remaining enzymatic activity of conjugated enzyme was detected via casein assay [25] .
The polymers were dissolved and the particles were dispersed at a concentration between 0.5 and 1 mg/mL in PBS 50 mM pH 8 containing 2 mM EDTA and 5 mM L-cysteine. The 
Intestinal mucus collection
Pig small intestines were obtained from a local abattoir immediately after slaughter and transported on ice to the laboratory. Sections of the intestines that did not visibly contain chyme were cut into ~15 cm lengths and mucus was removed. To remove the mucus gentle pressure was applied to one end of the length with the fingers and continuously applied unidirectionally to the opposite end. If the mucus contains debris the mucus was cleaned as follows. The mucus was gently stirred (<100 rpm) for 1 h at 4°C in sodium chloride (0.1 M)
at a ratio of 1 g mucus to 5 ml sodium chloride. The mixture was then centrifuged at 9000 rpm (10,400 x g) at 10°C for 2 h. The supernatant was discarded as well as the granular material at the bottom. The clean portion of the mucus was added to half the volume of sodium chloride (0.1 M) used for first washing. This was stirred (<100 rpm) for 1 h at 4°C
and then centrifuge at 9000 rpm at 10°C for 2 h. The supernatant was discarded and only the clean portion of the mucus was collected. Cleaned mucus (Imucus) was stored in aliquots at -20°C until use.
Mucin purification from porcine mucus
Mucus gel was collected as described above but added to a cocktail of enzyme inhibitors in phosphate buffer, pH 6.8 [26] . The mucus was not cleaned prior to mucin purification. The mucin (Imucin) was purified following the protocol described by Taylor et al., with the addition of a second caesium chloride gradient to further remove cellular debris from the glycoprotein component of mucus. All freeze dried sample were stored at -20oC until used.
Permeation study
The permeation ability of the prepared NPs was investigated by the rotating tube technique [27] . Plastic tube with a length of 30 mm and a diameter of 4 mm were filled in with Imucus exploiting a syringe without needle. One end of the tube was closed with parafilm, on the other end 100 µL of NPs, (previously resuspended by means of probe sonication for 10 sec in simulated intestinal fluid without pancreatin (SIF) (1 mg/mL)), was added. For each sample six replicates were prepared. After preparation the tubes were incubated at 37°C for 4 h under a constant horizontal stirring (≈50 rpm). A scheme representing the system is illustrated in Figure 1 . Thereafter, the tubes were frozen at -80°C and cut into slices of 2 mm length. Each slice was incubated with 150 µL DMSO, left overnight at room temperature protected from light and then ultrasonicated for 1 h. After centrifugation for 2 min at 13400 rpm (12100 x g) the fluorescence intensity of the supernatant (λex 578 nm, λem 613 nm) was determined in order to assess the depth of particles diffusion into the mucus. As control, the test was run each time with a tube filled with Imucus without NPs. The obtained fluorescence intensity of the Imucus was subtracted to the fluorescence intensity of the samples. 
3.11.Pulsed-gradient spin-echo NMR assessment of mucin mobility
Pulsed-gradient spin-echo NMR (PGSE-NMR) measurements were performed on a Bruker DMX400 NMR spectrometer operating at 400 MHz ( 1 H) using a stimulated echo sequence [28] . All the experiments were run at 37ºC using the standard heating/cooling system of the spectrometer to an accuracy of ±0.3ºC. All solutions were prepared from stock solutions and made up in SIF with the exception that D 2 O was used in place of H 2 O. The NPs formulations (containing calcium chloride and trehalose) were dispersed in SIF to a concentration of 0.5wt% NPs (equivalent to 7.5wt% of formulation). Imucin was then dissolved in the respective samples (final concentration 5wt%) and left to equilibrate for 24h. 0.6 mL were transferred to 5 mm o.d. NMR tubes (Willmad NMR tubes form Sigma-Aldrich).
Generally, the self-diffusion coefficient, D, is deduced by fitting the attenuation (decay) of the integral for a chosen peak to eqn.1,
where A is the signal intensity and k=-γ 2 G 2 δ the diffusion time, δ the gradient pulse length, and G is the gradient field strength. The gradient pulses are ramped to their desired value over a ramp time, σ, typically 250 µs.
For complex spectra such as those encountered here, the diffusion data are better analysed by fitting to this equation the entire bandshape using "CORE", a program devised to resolve the various components present in such data [29] . CORE permits the selection of significant regions of peak intensity within the spectra as well as the ability to "mask out" any unwanted All experiments were conducted at 37 °C. NPs and free enzymes were incubated with Imucus for 3 hours prior to measurement. The concentration of free enzyme in the samples was chosen to be equivalent to the amount of enzyme present in the samples containing enzyme conjugated NPs. All scattering data were (a) normalized for the sample transmission, (b) background corrected using a quartz cell filled with D 2 O, and (c) corrected for the linearity and efficiency of the detector response using the instrument specific software package.
Spin-echo small angle neutron scattering (SESANS) is a newer technique allowing the determination of material structure in the length range between 300 and 6000 nm. In this experiment, the neutron beam was split and the two halves polarized. Since polarized and non-polarized neutrons probe structure differently, the ratio of their intensities becomes a measure of any structure present, over a distance scale defined by the evolution period used in the experiment. The latter allows us to extend the lengthscale probed by several orders of magnitude. In both experiments, the effect of free enzymes or enzyme conjugated NPs on the sample scattering was followed for a period of c.a. 5h.
3.13.Statistical data analysis
All experiments were performed with at least three replicates and the data are reported as ions. The characteristics of the NPs resuspended in SIF after lyophilization as mean of four different preparation per formulation are reported in Table 2 . Enzyme-conjugated and unmodified NPs were monodispersed with a diameter included between 235 nm and 285 nm.
The zeta potential resulted to be negative for all three formulations with slightly higher values for the enzyme-modified NPs. This decrease in negative charges for the modified NPs could confirm the formation of the covalent bound between the mucolytic agent and the carboxylic group of PAA. The NPs were stable during centrifugation and lyophilization with trivial variation in size and poydispersity index (data not showed). The enzyme content for PAA-PAP NPs and PAA-BRO NPs, assessed after treatment with 1.5wt% sodium dodecyl sulfate leading to particles disaggregation (confirmed by DLS measurement), was comparable for both products. On the contrary, BRO maintained an higher enzymatic activity compared to the native enzyme in respect to PAP. The enzyme activity loss after NPs formation was equal to 57% and 24% for PAA-PAP NPs and PAA-BRO NPs, respectively. 
Cytotoxicity test
The cytotoxycity of polymers and NPs was tested in vitro via resazurin assay. Both PAP modified polymer and NPs resulted to be not toxic at all the concentrations tested. PAA-BRO was found to be more toxic compared with PAA-PAP with a cell availability of about 50% at all concentrations tested. On the contrary, BRO functionalized NPs were not significantly toxic at concentration lower then 0.2 mg/mL (Figure 2) . Table 3 .
As may be seen, the diffusion coefficient of mucin is only weakly affected by the blank PAA NPs confirming the absence of any significant attractive interactions between the PAA and the mucin gel. On the other hand, enzyme conjugated NPs lead to a 2 fold increase in Imucin diffusivity, indicating that the Imucin is more mobile due to the destruction of its structure.
Precisely, Imucin showed a greater diffusion coefficient ration when incubated with PAA-BRO NPs (2.4) compared to PAA-PAP NPs (1.9). It is also worth noting that the sample length scale characteristic for the density distribution. 23 
DISCUSSION
The formulation of a nanoparticulate carrier exploiting mucolytic agents able to cleave the glycoprotein substructures of mucus is a suitable strategy to improve drug oral bioavailability.
Within this research the permeation ability of two NPs systems decorated with mucolytic agents was compared. One system bearing PAP showed enhanced permeation property compared to bare NPs in a preliminary in vivo study. The other system bearing BRO should possess at least equal permeation ability, according to rheological tests [7] , but being more tolerated by patient, according to human in vivo tests [18] . The cytotoxicity of polymers and particles was assessed by resazurin test. This assay was choose as no need of medium removal after sample incubation is needed. In fact, during the 4 h experiment the cells can detach from the bottom of the wells due to the action of the proteolytic agents leading to false results in case of medium removal. On the one hand, the polymer PAA-BRO resulted to be more toxic than PAA-PAP on Caco-2 cells. On the other hand, both types of particles exhibit low toxicity when incubated at concentrations lower than 0.2 mg/mL.
As particle size and surface charge of the two types of particles were similar, the difference in 
t l i m i t e d t o t h e m o l e c u l a r w e i g h t , t h e p o l y d i s p e r s i t y o f t h e d i f f u s i n g s p e c i e s , t h e
heterogeneity in gel (physical) structure and/or heterogeneity in the mucin (chemical) structure. Therefore, the transport of NPs through such a gel will obviously be dependent on the underlying dynamics of the gel itself (e.g. rheology), superimposed on the effects any interactions between the NPs and the mucin or other components present in the mucus (e,g, protein adsorption to the particle surfaces). Disentangling the relative importance of the underlying gel dynamics and any further retardation of the particles due to specific binding, is essential if one is to isolate the effects of cleavage of the gel, and thus, optimise the delivery strategy.
To this end, the permeation of the NPs through mucus gels, which is a net effect of all interactions, may be compared with the NMR determined diffusion of the gel, which is limited to the structure of mucin itself. Therefore, consider first the rather coarse diffusion coefficient ratio derived from the weighted averages of the fast and slow components. When incubated with PAA-PAP and PAA-BRO NPs there is an increase in the rate of diffusion of the mucin, consistent with the proteolytic cleavage of the mucin strands, leading to polymers of lower molecular weight that will inherently possess a larger diffusion coefficient. This observation confirms that NPs surface decoration with mucolytic enzymes leads to increased permeation. Moreover, it appears that PAA-BRO NPs have the most significant effect on the mucin gel diffusion compared with PAA-PAP NPs. In fact, PAA-BRO NPs action leads to a substantially increased (x10) rate of diffusion of the slow component. These increases are comparable to the increases observed in the permeation study, suggesting a strong correlation between the two facets of the system. However, further work is required to understand the mode of action of the enzyme decorated NPs in order to more fully contrast the relative merits of PAP and BRO, in order to draw out stronger correlations with the permeation enhancement observed in the in vitro assay.
Taken together, the two scattering experiments reinforce the insights gained from the diffusion analysis. The bare particles do not lead to any large scale destruction in the structure and thus their mobility through the gel is somewhat limited. The surface decorated particles induce a loss of structure on a long lengthscale but with little effect on the conformation of the constituent polymers. The simple conclusion may be drawn is that the enzymes induce a very localized destruction in cross-linking density, leading to their greater mobility through the mucus associated with a greater mobility of the mucus itself. What is not clear from this data is precisely how the reduction in cross-linking density is achieved but it is known that both enzymes possess a broad specificity. PAP exhibits a preference for hydrophobic amino acid at position P2 especially for Phe and Tyr and for Gly, Met, Cys and Arg at position P1 and does not accept Val at position P1' [32] , whereas BRO preferentially cleaves the carbonyl terminal site of lysine, alanine, glycine and tyrosine [33] .
CONCLUSION
With the aim to design new oral DDSs able to overcome the intestinal mucus barrier PAP and BRO were conjugated to PAA. With these modified polymers NPs could be formulated presenting similar physic-chemical properties in term of particles size, zeta potential and enzyme content. The ability of the NPs in permeating porcine mucus and the changes in the mucus gel layer structure provoke by these systems were evaluated providing an inside from a nanometer to a microns lengthscale. The results obtained from the different technique used showed a strong correlation. In all tests BRO modified NPs exhibit the most significant effect in altering the mucus structure and the higher performance in permeating a fresh mucus layer compared to PAP conjugated NPs. Accordingly, the modification with BRO can further improve the permeability of PAA NPs and, therefore, this system can be exploited as a drug carrier able to transport the therapeutic payload through the mucus barrier and consequently able to improve the bioavailability of orally administered drugs.
CAPTIONS: · Nanoparticles were formulated with papain and bromelain modified poly(acrylic acid) · Inside from a nm to a μm lengthscale of particles mucus permeation ability is given · Particles bearing bromelain show higher permeation ability then papain particles · Bromelain particles exhibit the most relevant effect in altering mucus structure · Bromelain decorated particles can be exploited as oral drug delivery system
